JNK

JNK is a stress-activated MAPK that phosphorylates the N-terminal transactivation domain of c-Jun and regulates proliferation, apoptosis, motility, metabolism, and DNA repair[1]. Mechanistically, MKK4 and MKK7 increase JNK activity through phosphorylation, linking development and stress responses to downstream transcriptional control[2]. In disease models, dysregulated JNK signaling contributes to neurodegeneration, chronic inflammation, cancer, ischemia/reperfusion injury, and apoptosis-related pathology[1][3]. Compared with related isoforms, JNK1 and JNK2 are widely expressed, whereas JNK3 is mainly expressed in the brain, with lower expression in heart and testis[4]. This isoform distinction is experimentally important because JNK3 disruption protected mice from kainic acid-induced seizure activity and hippocampal neuronal apoptosis[5]. For experimental applications, SP600125 provides a reversible ATP-competitive JNK inhibitor that blocks JNK1/2/3 and supports pathway-dissection studies, although inhibitor-based conclusions require target-specific validation[6].